Breaking News Instant updates and real-time market news.

ORGO

Organogenesis

$8.01

0.07 (0.88%)

, TDOC

Teladoc

$51.97

-1.16 (-2.18%)

10:11
04/17/19
04/17
10:11
04/17/19
10:11

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Organogenesis (ORGO) initiated with an Outperform at Oppenheimer. 2. Teladoc (TDOC) initiated with an Overweight at Stephens. 3. Solar Capital (SLRC) initiated with an Outperform at Raymond James. 4. Principia Biopharma (PRNB) initiated with a Buy at Stifel. 5. Aurora Cannabis (ACB), HEXO Corp (HEXO), Canopy Growth (CGC), and Performance Food Group (PFGC) initiated with a Buy at BofA/Merrill while Cronos Group (CRON) was initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ORGO

Organogenesis

$8.01

0.07 (0.88%)

TDOC

Teladoc

$51.97

-1.16 (-2.18%)

SLRC

Solar Capital

$21.37

0.03 (0.14%)

PRNB

Principia Biopharma

$29.16

(0.00%)

ACB

Aurora Cannabis

$8.95

0.11 (1.24%)

HEXO

HEXO Corp

$6.17

0.12 (1.98%)

CRON

Cronos Group

$15.88

-0.02 (-0.13%)

CGC

Canopy Growth

$42.64

0.89 (2.13%)

PFGC

Performance Food Group

$41.01

0.3 (0.74%)

  • 30

    Apr

  • 07

    May

  • 09

    May

  • 10

    May

  • 05

    Jun

ORGO Organogenesis
$8.01

0.07 (0.88%)

04/16/19
OPCO
04/16/19
INITIATION
Target $11
OPCO
Outperform
Oppenheimer starts 'regenerative medicine story' Organogenesis at Outperform
Oppenheimer analyst Steven Lichtman initiated coverage of Organogenesis with an Outperform rating and $11 price target. The company has a "diverse product set at different levels of complexity and price points that address a wide spectrum of wounds and musculoskeletal injuries," Lichtman tells investors in a research note. The analyst sees Organogenesis' markets as growing more than high-single digits and not highly penetrated. He calls the company as a "well-positioned regenerative medicine story."
04/11/19
RHCO
04/11/19
INITIATION
Target $11
RHCO
Buy
Organogenesis initiated with a Buy at SunTrust
SunTrust analyst Bruce Nudell initiated Organogenesis with a Buy rating and a price target of $11. The analyst is positive on its position in the Advanced Would Care product segment and the Surgical & Sports Medicine segment focusing on musculoskeletal injuries. Nudell is modeling 11% annualized revenue growth through 2023, with breakeven cash flow reached by 2023.
04/16/19
OPCO
04/16/19
INITIATION
Target $11
OPCO
Outperform
Organogenesis initiated with an Outperform at Oppenheimer
Oppenheimer initiated Organogenesis with an Outperform and $11 price target.
04/12/19
BTIG
04/12/19
INITIATION
Target $12
BTIG
Buy
Organogenesis initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman initiated Organogenesis with a Buy rating and a price target of $12, citing the company's "expansive portfolio, history of execution, and improved capital structure". The analyst also notes that the company has been in the wound market since 1998, becoming "one of the largest pure-play companies in the fast growing and underpenetrated Advanced Wound Care market." Zimmerman further points to Organogenesis having built a $200M revenue business with its "stalwart wound products Apligraf and Dermagraft", with faster growing PuraPly for early wound intervention, and believes that it can capture more market share from some of its struggling competitors.
TDOC Teladoc
$51.97

-1.16 (-2.18%)

04/01/19
PIPR
04/01/19
NO CHANGE
Target $86
PIPR
Overweight
Teladoc oversold on Aetna contract confusion, says Piper Jaffray
Piper Jaffray analyst Sean Wieland believes some confusion over Aetna's intentions have pressured the shares of Teladoc (TDOC). The confusion lies in the fact that this was a "Request for Price" and not a "Request for Proposal," Wieland tells investors in a research note. However, his channel checks indicate there isn't any intention of CVS Health's (CVS) Aetna switching vendors. To the contrary, we've seen companies do this in front of a contract expansion, when they need to provide the board with benchmark pricing data to prove they are not overpaying, says the analyst. As such, he believes potential risk related to Teladoc's Aetna contract is minimal. Further, Wieland sees upside to Teladoc's initial guidance on stronger utilization trends as "telemedicine continues to go mainstream." He views the stock as oversold and reiterates an Overweight rating with an $86 price target.
04/08/19
PIPR
04/08/19
NO CHANGE
Target $86
PIPR
Overweight
Final CMS rule 'another win' for telemedicine industry, says Piper Jaffray
The Centers for Medicare & Medicaid Services on Friday issued a final that marks "another win" for the telemedicine industry, Piper Jaffray analyst Sean Wieland tell investors in a research note. Beginning 2020, Medicare Advantage plans will cover various telehealth services, including phone/video visits for medical or mental health needs, says the analyst. He believes there is a "strong value proposition" for health plans to promote these services to their beneficiaries, and that Teladoc is well positioned to gain from this trend. Wieland reiterates an Overweight rating on Teladoc shares with an $86 price target.
04/16/19
SPHN
04/16/19
INITIATION
Target $75
SPHN
Overweight
Teladoc initiated with an Overweight at Stephens
Stephens analyst Jacob Johnson initiated Teladoc with an Overweight rating and a price target of $75, saying the company is an "industry leader" in the telehealth industry which is undergoing "considerable growth" that is still in its "early innings". The analyst also notes that any M&A by Teladoc should "increase the value of its platform by adding capabilities and geographies", adding that while its gross margins may decline as a result of a "shifting revenue mix," the company's operating leverage should result in expanding EBITDA margins. Johnson further states that Teladoc shares are not cheap, but still trade "at a discount to high-growth healthcare and tech peers."
04/16/19
SPHN
04/16/19
INITIATION
Target $75
SPHN
Overweight
Teladoc initiated with an Overweight at Stephens
Stephens initiated Teladoc with an Overweight and $75 price target.
SLRC Solar Capital
$21.37

0.03 (0.14%)

04/16/19
RAJA
04/16/19
INITIATION
Target $22.5
RAJA
Outperform
Solar Capital initiated with an Outperform at Raymond James
Raymond James analyst Robert Dodd initiated Solar Capital with an Outperform and $22.50 price target.
04/16/19
RAJA
04/16/19
INITIATION
Target $22.5
RAJA
Outperform
Raymond James starts Solar Capital with Outperform, $22.50 target
Raymond James analyst Robert Dodd initiated coverage of Solar Capital with an Outperform rating and $22.50 price target. Solar Capital's earnings projections exceed its dividend, which is yielding 7.7%, and its total economic return profile is the top one-third of business development companies, Dodd tells investors in a research note. He believes the current valuation represents a discount to fair value.
11/28/18
11/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arcimoto (FUV) initiated with a Buy at Chardan. 2. Solar Capital (SLRC) initiated with an Outperform at Oppenheimer. 3. American Airlines (AAL) and Delta Air Lines (DAL) were initiated with a Positive at Susquehanna. 4. Huya (HUYA) initiated with a Neutral at JPMorgan. 5. Chesapeake Utilities (CPK) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/18
OPCO
11/28/18
INITIATION
Target $23
OPCO
Outperform
Solar Capital initiated with an Outperform at Oppenheimer
Oppenheimer analyst L. Allison Taylor Rudary started Solar Capital with an Outperform rating and $23 price target. The analyst believes specialty lending capabilities allow Solar Capital to achieve superior risk-adjusted returns and provide a favorable and differentiated risk profile compared to other BDCs.
PRNB Principia Biopharma
$29.16

(0.00%)

04/16/19
STFL
04/16/19
INITIATION
Target $45
STFL
Buy
Principia Biopharma initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Principia Biopharma with a Buy and $45 price target.
04/16/19
STFL
04/16/19
INITIATION
Target $45
STFL
Buy
Stifel starts Principia at Buy ahead of 'catalyst rich' Q4
Stifel analyst Derek Archila initiated coverage of Principia Biopharma with a Buy rating and $45 price target. The analyst is "bullish" on the shares ahead of a "catalyst rich" Q4. The company's lead asset PRN1008, a BTK inhibitor, should become "further de-risked" in two beachhead autoimmune/inflammatory conditions, pemphigus vulgaris and immune thrombocytopenia purpura, in Q4, Archila tells investors in a research note. The analyst thinks the Street does not fully appreciate the nuances of PRN1008's molecular design, which he believes will allow for improved safety and efficacy in autoimmune/inflammatory conditions.
10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/09/18
LEER
10/09/18
INITIATION
Target $34
LEER
Outperform
Principia Biopharma initiated with an Outperform on sales forecast at Leerink
Leerink analyst Geoffrey Porges started Principia Biopharma with an Outperform rating and $34 price target. The analyst cited his sales forecast for lead asset PRN1008 in orphan diseases, pemphigus and immune thrombocytopenia purpura, which combined he believes can reach peak sales of about $550M risk-adjusted at 65% and 35% probability-of-success, respectively.
ACB Aurora Cannabis
$8.95

0.11 (1.24%)

03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
04/17/19
BOFA
04/17/19
INITIATION
Target $11
BOFA
Buy
Aurora Cannabis initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Christopher Carey initiated Aurora Cannabis with a Buy and $11 price target saying it has a low cost production model, can protect margins in an oversupplied market, and the ability to serve a global market. Aurora also has long-time consumer investor, Nelson Peltz, as a Strategic Advisor which should accelerate partnership transactions, Carey wrote in a note to investors.
03/13/19
03/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Carnival (CCL) upgraded to Buy from Neutral at Goldman Sachs analyst Stephen Grambling citing the company accelerating its net unit growth from 2.5% in the last 3 years to 5% over the next 3 years and also believes that concerns about net yields in Europe are overblown. 2. Sanderson Farms (SAFM) upgraded to Neutral from Underweight at JPMorgan with analyst Ken Goldman saying he now views the stock's upside/downside risk as balanced. 3. Axis Capital (AXS) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying Axis is positioned for strong underwriting improvement. 4. Broadridge (BR) upgraded to Outperform from Market Perform at Raymond James with analyst Patrick O'Shaughnessy saying he believes Broadridge's current valuation offers investors an attractive entry point into a differentiated, high barrier to entry business. 5. Aurora Cannabis (ACB) upgraded to Buy from Hold at GMP Securities with analyst Martin Landry saying new high profile strategic advisor Nelson Peltz could be "instrumental" in facilitating partnership talks with large consumer packaged goods companies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
COWN
04/08/19
NO CHANGE
COWN
Cowen moderates near-term expectations for cannabis group on supply constraints
After hosting investor meetings with the management of Tilray (TLRY), Cowen analyst Vivien Azer said that Canada clearly remains supply constrained and that Tilray, with its asset-light approach, is overexposed to this supply tightness. Independent of commentary from the meetings with Tilray, Azer lowered her revenue estimates throughout her Canadian cannabis coverage as her current read suggests that Q1 growth will likely be modest. Despite her moderation of her near-term expectations, Azer keeps Outperform ratings on Aurora Cannabis (ACB), Canopy Growth (CGC) and Tilray (TLRY) and maintains a Market Perform rating on Cronos (CRON).
HEXO HEXO Corp
$6.17

0.12 (1.98%)

04/02/19
GHSC
04/02/19
NO CHANGE
GHSC
Neutral
Canopy estimates lowered at Seaport Global following peer reports
Seaport Global analyst Brett Hundley lowered his near-term revenue and EBITDA estimates for Canopy Growth (CGC) after recent earnings reports from HEXO Corp. (HEXO) and Cronos (CRON) highlighted broader Canadian industry inventory build and "marketplace inefficiency." He thinks it is prudent to be somewhat conservative related to store rollouts this spring along with the development of the nationwide edibles/beverages market later this year. Hundley keeps a Neutral rating on Canopy shares.
04/17/19
BOFA
04/17/19
INITIATION
Target $10
BOFA
Buy
HEXO Corp initiated with a Buy, a 'top pick in cannabis' at BofA/Merrill
BofA/Merrill analyst Christopher Carey initiated HEXO Corp with a Buy and $10 price target and naming it a "top pick in cannabis." Carey said HEXO offers a compelling relative valuation, an innovation-forward organization, potential additional partnerships, and a de-risked cannabis supply.
02/25/19
JEFF
02/25/19
INITIATION
JEFF
Underperform
HEXO Corp initiated with an Underperform at Jefferies
Jefferies analyst Owen Bennett initiated coverage of nine cannabis stocks, stating that his base-case "conservative" assumption is that the cannabis industry can grow in size to over $50B by 2029 from $17B in 2019. He started HEXO Corp. with an Underperform rating and C$5.60 price target, stating that he thinks the market "has taken the Molson deal as something more indicative of a stronger business than it is." Hexo "has a robust medical base but seems ill prepared for solo success beyond that," Bennett tells investors.
02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRON Cronos Group
$15.88

-0.02 (-0.13%)

04/17/19
BOFA
04/17/19
INITIATION
Target $13
BOFA
Underperform
Cronos Group initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst Christopher Carey initiated Cronos Group with an Underperform and $13 price target saying he not "comfortable" with valuation and screens the most expensive in his universe.
03/27/19
03/27/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Scotts Miracle-Gro (SMG) downgraded to Market Perform at Raymond James with analyst Joseph Altobello saying shares have bounced sharply and year-over-year comparisons in its U.S. Consumer business become notably more challenging entering the spring and are likely to limit further multiple expansion. 2. Kinder Morgan (KMI) downgraded to Neutral from Buy at Citi with analyst Mirek Zak saying after rallying 30% year-to-date, the shares shares appear fairly valued with growth opportunities looking balanced against downside risk over the near-term. 3. Acacia Communications (ACIA) downgraded to Underweight from Equal Weight at Morgan Stanley. 4. American Water (AWK) downgraded to Market Perform from Outperform at Wells Fargo, while California Water Service (CWT) was downgraded to Underperform from Market Perform. 5. Cronos Group (CRON) downgraded to Sell from Hold at Canaccord with analyst Matt Bottomley citing valuation and a soft start in the Canadian adult-use market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CGC Canopy Growth
$42.64

0.89 (2.13%)

04/17/19
BOFA
04/17/19
INITIATION
Target $70
BOFA
Buy
Canopy Growth initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Christopher Carey initiated Canopy Growth (CGC) with a Buy and $70 price target saying it is positioned to be a long-term leader in the global cannabis sector. Carey said Canopy has scale with 6M square feet of cultivation capacity, capital following the Constellation (STZ) $4B investment, and vision as it lays groundwork to excel in areas higher on the value chain.
04/05/19
MSCO
04/05/19
NO CHANGE
Target $230
MSCO
Overweight
Constellation Brands' FY20 guidance looks conservative, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian said he was surprised by the magnitude of the "relief rally" in Constellation Brands (STZ) shares following the company's Q4 report given that the company reported greater than expected near-term EPS dilution from its low-end wine sale, realized a lower than expected multiple on the wine transaction and unexpectedly did not provide forward guidance for Canopy Growth (CGC) equity losses. With that said, he sees "two clear positives" emerging from the quarter: the fact that fundamentals in the beer business remain solid and the fact that he sees solid visibility that Constellation can hit the high end of if $8.50-$8.80 FY20 EPS guidance, leaving aside Canopy equity losses. The analyst lowered his FY20 and FY21 EPS estimates to reflect dilution from the wine asset sale and trimmed his price target to $230 from $233, but he keeps an Overweight rating on Constellation shares.
04/12/19
PIPR
04/12/19
NO CHANGE
Target $60
PIPR
Overweight
Canopy Growth Q4 revenue estimate lowered at Piper Jaffray
Piper Jaffray analyst Michael Lavery trimmed his Q4 revenue estimates for Canopy Growth to reflect a more conservative build, based on early quarter Health Canada data. Based on April channel checks, product supply to retailers has recently improved, and stores are now maintaining some product inventory, Lavery tells investors in a research note However, Health Canada January industry data show industry momentum ramping up a bit more slowly than expected, adds the analyst. As such, Lavery lowered his Q4 revenue estimate for Canopy Growth to C$96.8M from C$117.6M. Capacity, scale and execution will continue to matter for the next 12-24 months, as growing supply catches up with strong demand in both Europe and Canada, says the analyst. He considers Canopy well positioned relative to its peers on these measures. Lavery keeps an Overweight rating on Canopy Growth shares with a $60 price target.
PFGC Performance Food Group
$41.01

0.3 (0.74%)

04/17/19
BOFA
04/17/19
INITIATION
Target $45
BOFA
Performance Food Group initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Christopher Carey initiated Performance Food Group with a Buy and $45 price target citing healthy growth with upside potential. Carey expects independent restaurant growth to reaccelerate in second half 2019 supported by salesforce expansion and views Vistar as a key differentiator with its high margins and increasing penetration in existing channels.
12/21/18
SBSH
12/21/18
INITIATION
Target $40
SBSH
Buy
Performance Food Group initiated with a Buy at Citi
Citi analyst Gregory Badishkanian started Performance Food Group with a Buy rating and $40 price target.
10/22/18
BUCK
10/22/18
INITIATION
Target $39
BUCK
Buy
Performance Food Group initiated with a Buy at Buckingham
Buckingham initiated Performance Food Group with a Buy and $39 price target.
11/14/18
LOOP
11/14/18
NO CHANGE
Target $42
LOOP
Buy
Loop Capital 'strongly' reiterates Buy on Performance Food after buyback plan
Loop Capital analyst Andrew Wolf points out that Performance Food Group's $250M buyback announced this morning is its first since the company went public in 2015. After speaking to management, the analyst believes the repurchase authorization signals the company believes the stock is undervalued and that current acquisition deal economics "are a bit rich." The analyst "strongly" reiterates a Buy rating on Performance Food, calling the stock one of his best ideas with $30% upside to his $42 price target.

TODAY'S FREE FLY STORIES

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:58
04/18/19
04/18
06:58
04/18/19
06:58
Hot Stocks
Travelers reports book value per share $92.94, up 7% from year-end 2018 »

Reports adjusted book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Hot Stocks
Breaking Hot Stocks news story on Travelers »

Travelers raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

CTG

Computer Task Group

$4.27

0.02 (0.47%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
Computer Task Group backs FY19 non-GAAP EPS view 30c-40c, consensus 33c »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SNAP

Snap

$11.75

0.08 (0.69%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Downgrade
Snap rating change  »

Snap downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
Travelers reports Q1 core EPS $2.83, consensus $2.74 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FSLR

First Solar

$60.70

0.17 (0.28%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Recommendations
First Solar analyst commentary  »

First Solar should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 17

    May

PPG

PPG

$117.39

-1.01 (-0.85%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
PPG backs FY19 adjusted EPS growth 7%-10%, consensus $6.24 »

"More broadly, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

CTG

Computer Task Group

$4.27

0.02 (0.47%)

06:56
04/18/19
04/18
06:56
04/18/19
06:56
Earnings
Computer Task Group reports Q1 non-GAAP EPS 6c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:54
04/18/19
04/18
06:54
04/18/19
06:54
Hot Stocks
PPG CEO says Q1 operating margins 'were higher than the prior year' »

"First quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:53
04/18/19
04/18
06:53
04/18/19
06:53
Hot Stocks
PPG says committed to finalizing strategic review be end of second quarter »

The company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

IRBT

iRobot

$129.26

-0.74 (-0.57%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Recommendations
iRobot analyst commentary  »

iRobot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Earnings
PPG sees Q2 EPS $1.76-$1.86, consensus $1.86 »

"As we look ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

MNK

Mallinckrodt

$19.12

-2.51 (-11.60%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Hot Stocks
Mallinckrodt announces results from gNO with EVLP study »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

PPG

PPG

$117.39

-1.01 (-0.85%)

06:51
04/18/19
04/18
06:51
04/18/19
06:51
Earnings
PPG reports Q1 adjusted EPS $1.38, consensus $1.21 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

LULU

Lululemon

$171.19

2.28 (1.35%)

06:51
04/18/19
04/18
06:51
04/18/19
06:51
Conference/Events
Lululemon to host analyst day »

Analyst day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SON

Sonoco

$60.98

-0.235 (-0.38%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Earnings
Sonoco raises FY19 base EPS view to $3.52-$3.62 from $3.47-$3.57 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 07

    May

  • 18

    Jul

  • 17

    Oct

DOV

Dover

$96.81

-0.66 (-0.68%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Earnings
Breaking Earnings news story on Dover »

Dover backs FY19 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 02

    May

VRAY

ViewRay

$7.26

-0.16 (-2.16%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Hot Stocks
ViewRay announces Minouge Medical as Canadian distributor of MRIdian »

ViewRay announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NICE

Nice

$130.90

2.04 (1.58%)

, VRNT

Verint

$60.20

-1.49 (-2.42%)

06:48
04/18/19
04/18
06:48
04/18/19
06:48
Upgrade
Nice, Verint rating change  »

JPMorgan upgrades Nice to…

NICE

Nice

$130.90

2.04 (1.58%)

VRNT

Verint

$60.20

-1.49 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco

$60.98

-0.235 (-0.38%)

06:48
04/18/19
04/18
06:48
04/18/19
06:48
Earnings
Breaking Earnings news story on Sonoco »

Sonoco sees Q2 base EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 07

    May

  • 18

    Jul

  • 17

    Oct

GM

General Motors

$39.99

0.42 (1.06%)

06:47
04/18/19
04/18
06:47
04/18/19
06:47
Periodicals
General Motors says Cadillac has gained popularity in China, Reuters reports »

General Motors'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 05

    Jun

SON

Sonoco

$60.98

-0.235 (-0.38%)

06:47
04/18/19
04/18
06:47
04/18/19
06:47
Earnings
Sonoco reports Q1 base EPS 85c, consensus 80c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 07

    May

  • 18

    Jul

  • 17

    Oct

DOV

Dover

$96.81

-0.66 (-0.68%)

06:47
04/18/19
04/18
06:47
04/18/19
06:47
Earnings
Dover reports Q1 adj. EPS $1.24, consensus $1.10 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 02

    May

AVY

Avery Dennison

$113.69

-2.68 (-2.30%)

06:46
04/18/19
04/18
06:46
04/18/19
06:46
Downgrade
Avery Dennison rating change  »

JPMorgan downgrades Avery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 18

    May

SYF

Synchrony

$33.22

0.06 (0.18%)

06:46
04/18/19
04/18
06:46
04/18/19
06:46
Earnings
Synchrony reports Q1 EPS $1.56, consensus 93c »

Reports Q1 CET1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 29

    May

  • 11

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.